Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Antipyrine

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Antipyrine?

Antipyrine is an investigational drug.

There have been 5 clinical trials for Antipyrine. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1^st 2011.

The most common disease conditions in clinical trials are Dysmenorrhea, Turner Syndrome, and Syndrome. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., University of Aarhus, and Currax Pharmaceuticals.

Summary for Antipyrine

US Patents	0
International Patents	0
US Patent Applications	4,081
WIPO Patent Applications	1,591
Japanese Patent Applications	386
Clinical Trial Progress	Phase 3 (2011-11-01)
Vendors	84

Recent Clinical Trials for Antipyrine

Title	Sponsor	Phase
Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults	Global United Pharmaceutical Corporation	Phase 2
Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media	Currax Pharmaceuticals	Phase 2
Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media	Pernix Theraputics LLC	Phase 2

See all Antipyrine clinical trials

Clinical Trial Summary for Antipyrine

Top disease conditions for Antipyrine

Top clinical trial sponsors for Antipyrine

See all Antipyrine clinical trials

US Patents for Antipyrine

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Harvard Business School

McKesson

McKinsey

Colorcon

Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.